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Purpose: The purpose of this study was to determine the outcome of endovascular aneurysm repair in a defined geographic
region during the first 2 years after Food and Drug Administration approval of a new endovascular device.
Method: Clinical results of all attempted endovascular aneurysm repairs from 1999 to 2001 with the AneuRx stent graft
in the northern California/Nevada region were reviewed. All cases performed in 23 hospitals by 21 endovascular
treatment teams were included on an intent-to-treat basis. Community physician training, proctoring, and assistance in
case selection was provided by the manufacturer, with outcome monitored by external physician observers and clinical
vascular specialists. Results in 22 community hospitals were compared with concurrent results in the regional university
hospital training center and with results from the controlled, multicenter AneuRx clinical trial.
Results: Endovascular aneurysm repair was attempted in 257 patients by 20 endovascular teams working in 22 community
hospitals. The mean number of cases per team was 13  2 (range, 1 to 36). Patient age was 74.1  6.5 years (89% men
and 11% women), and 29% of patients were not candidates for open surgical repair because of multiple medical
comorbidities. Mean aneurysm diameter was 5.7 0.8 cm. The endoluminal stent graft was successfully deployed in 254
patients (98.8%). In two patients, iliac access could not be obtained, and in one case, the iliac limb was misdeployed and
the patient underwent successful open surgical repair. The surgical conversion rate was two of 257 patients (0.8%). The
30-day mortality rate was 1.2%, with one patient dying of stroke, one of multisystem organ failure, and one of cerebral
hemorrhage. No device-related deaths occurred. Secondary procedures were performed in 8% of patients. Primary graft
patency rate was 98%, and secondary graft patency rate was 100%. Concurrent university training center experience with
100 patients with similar characteristics and aneurysm size was not statistically different (deployment success rate, 100%;
30-day mortality rate, 0%; surgical conversion rate, 0%; secondary procedure rate, 8%). No aneurysm ruptures and no late
surgical conversions have been seen in either the community or university experience, with follow-up periods extending
to 2 years.
Conclusion: Early results of endovascular aneurysm repair introduced into community practice are favorable. Initial
community experience, with clinical support from the manufacturer, does not appear to differ significantly from
concurrent results in the university training center or from results reported from the multicenter controlled clinical trial
with the same device. (J Vasc Surg 2002;36:226-33.)
Ten years have passed since the first report from Parodi,
Palmaz, and Barone1 of abdominal aortic aneurysm repair
with an endoluminal prosthesis. This less invasive approach
to treat aortic aneurysms stimulated intense investigation
and innovation in academic and clinical centers along with
development by industry of a number of promising endolu-
minal devices.2-8 Two endoluminal devices (the Medtronic
AneuRx stent graft, Santa Rosa, Calif, and the Guidant
Ancure, Menlo Park, Calif, endoluminal prosthesis) have
completed multicenter controlled clinical trials comparing
endoluminal repair with standard open surgical repair and
received Food and Drug Administration (FDA) market
approval on September 28, 1999. FDA approval included a
requirement for the device manufacturer to provide physi-
cian training and patient education and to extend follow-up
of clinical trial patients to 5 years. Both manufacturers have
introduced the technology to community-based vascular
practice and have implemented physician training programs
and clinical support to new users. The effectiveness of this
training and the initial results in broad-based community
practice have not yet been reported.
Two years have now passed since FDA approval of the
AneuRx stent graft, and the 4-year results of all patients
treated in the clinical trial have now been published.8
Although the results of endovascular repair with a variety of
endoluminal devices in centers of excellence have been
published and widely disseminated,9-15 the results in com-
munity practice and in hospitals not participating in clinical
trials are not well known. The purpose of this investigation
is to review the results of endovascular aneurysm repair in
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all hospitals in a defined geographic area with a single FDA
approved device, the AneuRx stent graft, in the 2 years
since market approval and to compare it with the published
results from the AneuRx clinical trial. Within this region,
the results in 22 community hospitals were compared with
the concurrent results in the regional university hospital,
which had participated in the multicenter clinical trial for
FDA approval and served as a training center for new users
of the AneuRx stent graft.
METHODS
We reviewed the results of all patients considered for
endovascular aneurysm repair with the AneuRx stent graft
in the northern California/Nevada region from September
28, 1999, to September 20, 2001. The northern Califor-
nia/Nevada region was defined by the manufacturer
(Medtronic AVE) for sales, marketing, training, and sup-
port purposes. The region was comprised of the northern
third of California and the northern half of Nevada (Fig 1)
and had a population base of 12 million people, which
represented 4.3% of the US population (Table I). The
Medicare population was 1.6 million and comprised 3% of
the US Medicare population.16 The region contained 70
hospitals that had performed one or more aortic aneurysm
repairs, including ruptures, from 1996 to 1997.16 During
the years 1999 to 2001, 23 of these hospitals performed
one or more endovascular aneurysm repairs with the FDA-
approved AneuRx stent graft.
Each community hospital physician team implanting
the AneuRx stent graft was trained at a clinical training
center that had extensive experience with the device, having
participated in the US AneuRx clinical trial. One of these
centers, Stanford University Hospital, is located in the
northern California region and served as a training center.
The training session included didactic teaching, in vitro
device deployment, case selection, and clinical case obser-
vation during a 2-day period. On-site proctoring of the
cases at each new hospital was provided by physicians
experienced in the use of the AneuRx stent graft. Assistance
with film reading and case selection and ongoing clinical
vascular specialist support was provided by the manufac-
turer. In addition, the manufacturer provided physicians
with clinical updates and follow-up teaching seminars.
Computed tomographic (CT) scan image and procedural
data on each patient were provided by the treating physi-
cian, and completeness of case reporting was confirmed
from device utilization data provided by the manufacturer.
Postoperative evaluation was performed in accordance with
the manufacturer’s guidelines; results were reported by the
treating physicians and recorded in a central data registry.
Community hospital results were combined and compared
with concurrent results at Stanford University Hospital and
with the published results from the multicenter US AneuRx
Clinical Trial.3,8
Results were expressed as the mean  standard devia-
tion, and differences between groups were compared with
2 analysis. P values of less than .05 were considered
significant.
RESULTS
Community hospitals. Since September 28, 1999,
20 physician teams, working in 22 hospitals in the northern
California/Nevada region, have been trained to perform
endovascular aneurysm repair with the AneuRx stent graft
and have begun using the device (Appendix, online only).
The physician teams were comprised of multiple specialties
that included: 11 vascular surgery-interventional radiology
(55%) teams, four vascular surgery teams (20%), three
vascular surgery-interventional radiology-interventional
cardiology teams (15%), and two vascular surgery-interven-
tional cardiology teams (10%). The average number of
patients treated by each endovascular team was 13  2,
with a range of one to 36 cases (Fig 2). The average number
of physician proctored cases per team was six, with a range
of two to 10. The number of procedures performed by
specialty-based teams in the community were as follows:
vascular surgery-interventional radiology team, 147 proce-
dures (57%); vascular surgery team, 76 procedures (30%);
Fig 1. Northern California/northern Nevada region.
Table I. Northern California/northwestern Nevada
region
Population base 12 million 4.3% of US population
Medicare population 1.6 million 3% of US population
Hospitals treating AAA 70
Hospitals using
AneuRx stent graft
23 33%
AAA, Abdominal aortic aneurysm.
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vascular surgery-interventional radiology-interventional
cardiology teams, 32 procedures (12%); and vascular sur-
gery-interventional cardiology teams, two procedures (1%;
Fig 3). Vascular surgeons were involved with all 257 pro-
cedures (100%), interventional radiologists with 179 cases
(70%), and interventional cardiologists with 34 cases
(13%). No difference was seen in outcome on the basis of
the number of cases performed, specialty involvement in
the treatment procedures, or whether or not physician
proctors were present.
The 257 community patients included 228 men (89%)
and 29 women (11%), with a mean age of 74  7 years
(Table II). Seventy patients (29%) were considered as non-
candidates for open surgical repair because of the severity of
medical comorbidities, including severe coronary artery
disease, congestive heart failure, oxygen dependence,
chronic obstructive pulmonary disease, morbid obesity,
and future heart transplant (n  2). Preoperative aortic
diameter was 5.7  0.8 cm, with a range of 3.5 to 9.8 cm.
The indication for treatment of the 3.5-cm aortic aneurysm
was for an enlarging 4-cm common iliac aneurysm. Endo-
vascular device deployment was successful in 254 patients
(98.8%). In two patients, satisfactory iliac access could not
be obtained and the endovascular device could not be
introduced into the aneurysm. One patient underwent
successful open surgical repair of the aneurysm. The other
patient’s procedure was terminated, and no further attempt
to repair the aneurysm was carried out because the patient
was believed to be at prohibitive operative risk because of
severe three-vessel coronary disease for which the patient
refused surgery. This patient remains well, and the 6.4-cm
aneurysm has not ruptured. In one patient, the contralat-
Fig 2. Procedure volume by community endovascular team.
Fig 3. Procedure volume by endovascular team specialty. VS,
Vascular surgery; IR, interventional radiology; IC, interventional
cardiology.
Table II. Patient characteristics
Community
hospitals
University
hospital
Phase II clinical
trial8
No. 257 100 416
Age (y) 74  7 74  6 73  8
Range (y) 49 to 90 60 to 90 45 to 93
Men 89% 88% 89%
Women 11% 12% 11%
AAA diameter (cm) 5.7  0.8 5.5  0.7 5.6  0.9
Range (cm) 3.5 to 9.8 3.9 to 9.0 3.3 to 9.0
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eral iliac limb was misdeployed, resulting in a large type I
endoleak. This patient underwent successful open surgical
repair. Thus, the early surgical conversion rate was two of
257 patients (0.8%). No late surgical conversions occurred.
Three patients died within 30 days of the procedure:
one because of a stroke 6 days after the procedure, one
because of multisystem organ failure 5 days after the pro-
cedure, and one because of cerebral hemorrhage on day 3
after the procedure. The 30-day procedure mortality rate
was 1.2%. No device-related deaths occurred.
Six major events, including failure to successfully intro-
duce the stent graft in three patients (with surgical conversion
in two), and deaths in three patients were reviewed to deter-
mine whether low-volume hospitals or the early learning curve
may have been factors. Only one of these events occurred
among the first 10 cases performed by each endovascular
team. This event was a death from multisystem organ failure
and occurred in the fifth case performed by one endovascular
team. Thus, patients treated early in the learning process with
this new device do not appear to be at higher risk.
Completion angiography and postprocedure imaging
with contrast CT scanning and abdominal radiographs
were performed to confirm stent graft fixation and com-
pleteness of aneurysm exclusion (Fig 4). Endoleaks were
identified in 30 patients (12%). Of these, five (2%) were
type I endoleaks and 26 (10%) were type II endoleaks.
Follow-up imaging was performed at 1 month, 6 months,
and 12 months, as per the manufacturer’s recommenda-
tion. The average follow-up time since the endovascular
procedure was 9.6  5.6 months. Follow-up imaging
studies revealed that three aneurysms increased in size (1%).
Secondary procedures were performed in 21 patients
(8%). These included five extender cuff procedures to se-
cure fixation, four catheter-based procedures to treat en-
doleaks, six procedures for limb thrombosis or correction
of limb kinks, and six procedures to correct femoral artery
or groin incision problems. All six limb thromboses oc-
curred in hospitals performing one of their first 10 cases.
These thromboses were primarily caused by femoral artery
repair problems, suggesting that greater attention to clo-
sure techniques with endarterectomy or patching may have
avoided these problems. Iliac conduit access was used in
seven patients (3%) for introduction of the device, and no
patient had a complication. The primary graft patency rate
was 98%, and the secondary graft patency rate was 100%.
No device-related deaths and no aneurysm ruptures oc-
curred in follow-up to 2 years.
University training center. Stanford University Hos-
pital was a clinical investigation site during the multicenter
clinical trial and served as a training center for community
hospitals after FDA approval of the AneuRx device. A total
of 100 patients underwent treatment with the AneuRx
stent graft at Stanford University Hospital in the 2 years
since market approval (1999 to 2001). The physician team
consisted of vascular surgery-interventional radiology for
all 100 cases. Eighty-eight men and 12 women, with a
mean age of 74  6 years, participated (Table II). Preop-
erative aortic diameter was 5.5  0.7 cm, with a range of
3.9 to 9.0 cm. The patient with the 3.9-cm aneurysm had
symptoms and documented enlargement.
Endovascular device deployment was successful in all
patients (100%). Iliac conduit access was used in four
patients (4%) for introduction of the device or hypogastric
artery revascularization without complication. No early or
late surgical conversions occurred in these patients. No
patients died within 30 days of the procedure, and no
aneurysm ruptured.
Postprocedure imaging was performed with contrast
CT scanning, duplex ultrasound scan imaging, and abdom-
inal radiographs. Endoleaks were identified in 18 patients
(18%). Of these, one type 1 endoleak (1%) and 17 type II
endoleaks (17%) were seen. Follow-up imaging was per-
formed at 1 month, 6 months, and 12 months, with a mean
follow-up time since the procedure of 11.1  4.3 months.
Follow-up imaging showed that one aneurysm (1%) had
increased in size, with 99% of aneurysms remaining stable
or decreasing in size. Secondary procedures were per-
formed in eight patients (8%). These procedures included
six extender cuff procedures to secure fixation, one cathe-
ter-based procedure to treat a type II endoleak, and one
thrombectomy for a limb thrombosis. Primary graft pa-
tency rate was 99%, and secondary graft patency rate was
100%. No device-related deaths or aneurysm ruptures oc-
curred in follow-up to 2 years. No statistically significant
differences were seen between university hospital results
and the community hospital experience.
DISCUSSION
Endovascular aneurysm repair with the AneuRx stent
graft was first performed on June 3, 1996, with the initia-
tion of phase I of the US AneuRx Clinical Trial. Phase II of
Fig 4. Postoperative completion angiogram and postprocedure
contrast CT scan after endovascular aneurysm repair.
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the trial included 13 clinical centers that compared endo-
vascular repair with standard open surgery.3 Six additional
centers were added to the clinical trial during the phase III
investigation, bringing the total number of clinical centers
to 19.8 These centers were located throughout the United
States and were selected because of their experience in open
aneurysm surgery and skill and experience in endovascular
treatments. Each clinical center was comprised of a multi-
disciplinary team, which included experienced vascular sur-
geons and interventional radiologists or interventional car-
diologists or both. The results for all patients treated during
the course of the AneuRx clinical trial in these centers,
including patients for compassionate use and at high risk,
excluded from the controlled clinical trial protocol, have
recently been published. Among all 1192 patients enrolled
in the clinical trial, successful device deployment was
achieved in 98%, with a 30-day mortality rate of 2%. Only
1.5% of patients needed early surgical conversion, and
aneurysm rupture was prevented in 99.5% of patients.8
Excellent results with elective open surgical repair of
aortic aneurysm have consistently been reported from high-
volume clinical centers with low operative mortality
rates.17-20 However, population-based experiences21-23 re-
port higher operative mortality rates for open aneurysm
repair, and evidence shows that low-volume centers and
low-volume surgeons have inferior results with open aneu-
rysm repair compared with high-volume hospitals.22 This
has led some to question whether the new endovascular
treatment technology should be rapidly disseminated into
community practice or whether this new approach to treat-
ing aortic aneurysms should be limited to high-volume
multidisciplinary aneurysm treatment centers that have
proved to be effective in clinical trials. Clearly, endovascular
aortic aneurysm repair requires a new skill set, using imag-
ing methods and both open surgical and endovascular/
interventional techniques, which have not been part of
physician-training programs in the past. Therefore, how
effective endovascular aneurysm repair would be in the
hands of inexperienced new users, once the new endovas-
cular devices were released to the market, was unclear. This
report provides the first comprehensive regional data on
early results after introduction of this new endovascular
technology to community practice.
In accordance with FDA stipulations at the time of
market approval, the manufacturer (Medtronic AVE) insti-
tuted a physician-training program and provided trained
clinical vascular specialists along with experienced physician
proctors to each new endovascular treatment team. The
training program included training of vascular surgeons,
interventional radiologists, and interventional cardiolo-
gists, with a focus on training of the team rather than the
individual to address the issue of combination of skills
necessary for endovascular repair. The effectiveness of this
training program, which included on-site proctoring, assist-
ance with case selection, and vascular specialist technical
support, is apparent in the results presented in this report.
We found that no significant difference was seen in
deployment success or early results in the northern Califor-
nia/Nevada region community hospitals from concurrent
results obtained in the university hospital training center or
from results reported from the phase II clinical trial (Tables
II and III) or the overall 4-year AneuRx clinical trial.8
Importantly, only one postoperative death occurred among
the first 10 patients treated by each of the 20 new endovas-
cular teams (200 patients), suggesting that the learning
curve is safe and that low-volume early stent graft users can
have excellent results if proper training and support are
provided. Combining both community hospital and Stan-
ford University hospital experience with 357 patients since
FDA approval of the AneuRx device, stent graft deploy-
ment was successful in 99% of patients and the 30-day
mortality rate was only 0.8%. Surgical conversion rate was
only 0.6%. Secondary procedure rate was 8%, no different
from the AneuRx clinical trial. Endoleaks were found in
13% of the 357 patients; however, whether endoleaks, in
and of themselves, are predictors of long-term adverse
outcome of endovascular aneurysm repair is not clear.24
The somewhat higher endoleak rate found in the university
experience may be the result of more extensive imaging
than is available or practiced in the community. No aneu-
rysm ruptures or device-related deaths were seen in this
experience. Although this early experience was favorable,
long-term outcomes are yet to be determined.
The population base for the northern California/Ne-
vada region was 12 million, and of this population, 1.6
million persons are Medicare beneficiaries. Seventy hospi-
tals performed at least one open aneurysm repair from 1996
to 1997, and the total number of aneurysms repaired in this
region during that year was 1342. Of these, 1070 (80%)
were elective aneurysm repairs.16 Thus, the average num-
ber of elective aneurysm repairs per hospital, with the
capability of treating aneurysms in 1996, was 16. The
average number of endovascular aneurysm repairs per en-
dovascular team, in one third of these hospitals in the 2-year
period from 1999 to 2001, was 13. However, it should be
noted that hospitals and surgeons with only an occasional
aneurysm repair were unlikely to be interested in or selected
for the endovascular training program, leaving this to hos-
pitals or surgeons with aneurysm referrals and practices.
What proportion of the total regional aneurysm volume
Table III. Outcomes
Community
hospitals
University
hospital
Phase II
clinical trial8
No. of patients 257 100 416
Deployment success
rate
99% 100% 98%
Mortality rate (30 day) 1.2% 0% 2%
Surgical conversion rate 0.8% 0% 1.5%
Secondary procedure
rate
8% 8% 7%
Endoleak rate 12% 18% 13%
Primary patency rate 98% 99% 98%
Secondary patency rate 100% 100% 99%
Aneurysm rupture rate 0% 0% 0.5%
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was performed by these relatively high-volume centers is
not known. The current number of elective aneurysm
repairs performed in the northern California/Nevada re-
gion is not yet known; however, if the number of elective
open aneurysm repairs in the northern California/Nevada
region 5 years earlier (1996) is used as the denominator,16
then this early AneuRx experience represents approxi-
mately 17% of the number of aneurysms treated each year in
this region. Whether endovascular repairs are replacing
open surgical repair or whether the total number of aneu-
rysms being treated has increased is unclear. Reports from
individual centers that have begun endovascular treatment
programs suggest that the total number of aneurysms
treated has increased,25 but this increase may be the result
of changes in referral patterns rather than an overall increase
in the number of aneurysms being treated. However, it is
possible that a true increase in the number of aneurysms
treated exists because of the inclusion of older and sicker
patients with severe medical comorbidities who previously
would have been excluded from consideration for aneu-
rysm treatment. Indeed, in this northern California/Ne-
vada experience, 29% of patients treated were considered to
be nonsurgical candidates because of prohibitive surgical
risk. Further study will clarify whether the total number of
aneurysms treated will increase because more patients at
poor risk will be offered treatment.
Lawrence et al26 reviewed the National Hospital Dis-
charge Survey data for the year 1994 and reported 32,389
nonruptured abdominal aortic aneurysms that were treated
surgically, with an operative mortality rate of 8.4%. The
authors proposed that this could be used as a national
standard of comparison for endovascular aneurysm repair.
The northern California/Nevada region’s 30-day mortality
rate of 0.6% for endovascular aneurysm repair in a broad-
based regional experience shows a much lower mortality
rate for endovascular repair than that expected for open
surgical repair.
Lawrence et al26 also found that the number of aneu-
rysm operations per thousand population varied by region,
with surgery rates more frequent in the Northeast and less
frequent in the West. This regional difference was con-
firmed with data from the Dartmouth Atlas of Vascular
Health Care.16 The rate of aortic aneurysm repairs in the
northern California/Nevada region per 1000 Medicare
enrollees from 1996 to 1997 was 0.84 compared with the
rate for the entire United States of 1.09. The explanation
for this difference is unclear. Whether the regional differ-
ences in aneurysm repair noted for open surgery will also be
found for endovascular repair is unknown.
No aneurysm ruptures occurred in the 357 patients
treated with the AneuRx stent graft in the northern Cali-
fornia/Nevada region, and thus, the primary objective of
aneurysm treatment has been achieved. Ruptures have been
reported from the clinical trial27 and have been primarily
related to an early prototype stiff bifurcation stent graft,
which was used in the first phase of the clinical trial.8
Ruptures that occurred in clinical trial patients have been
attributed to poor patient selection or imprecise placement,
resulting in insecure fixation of the device proximally, dis-
tally of the modular junction.27 Evidence of poor fixation
can be seen on postimplant imaging studies well before
rupture occurs, thus providing an opportunity to place
endoluminal stent graft extender cuffs to secure fixation
and prevent rupture. This is the rationale for follow-up
imaging studies after endovascular repair. These lessons,
learned from careful follow-up of clinical trial patients, have
been published and are taught during training for new
device users and during proctoring, case selection consul-
tations, and follow-up seminars. Nationwide, more than
9500 patients have been treated with the AneuRx stent
graft since FDA approval. Only two aneurysm ruptures
were reported in the United States after successful device
implantation during the first 18 months of clinical use.
Freedom from aneurysm rupture at 4 years with Kaplan-
Meier method analysis of clinical trial patients was 99%.8
Similarly, the surgical conversion rate in our experience
has been low, with only two of the 357 patients (0.6%)
needing open surgical repair. This rate compares favorably
with the 1.5% early surgical conversion rate in the AneuRx
clinical trial3 and is lower than the reported surgical con-
version rate with other endovascular devices of up to 10%.2
The initial community experience with the AneuRx
stent graft was favorable, with a 99% technical success in
device implantation and a low perioperative 30-day mortal-
ity rate, despite its application to a large number of patients
who were not candidates for open surgical repair. Thus, the
initial results of community endovascular treatment pro-
grams are encouraging. Long-term follow-up is needed to
determine the ultimate long-term success of endovascular
aneurysm repair and its effectiveness compared with open
surgery and its role in overall aneurysm treatment strategies.
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DISCUSSION
Dr Kaj Johansen (Seattle, Wash). The rate at which a new
technology is introduced into the practicing medical community
and the extent to which this occurs is poorly characterized and
documented. Dr Zarins provides us with interesting and poten-
tially useful data regarding diffusion of endovascular graft (EVG)
technology into the practicing vascular community in northern
California and northwestern Nevada over a 24-month period
ending in September 2001. He concludes that outcomes from
EVG insertion in a series of community hospitals in this geographic
region are highly technically successful, the effects of the learning
curve on outcomes appear to be modest, the results appear to be
volume-independent (that is, outcomes were not better, or
worse, in high-volume versus low-volume sites), and postinter-
vention aneurysm expansion and rupture rate—the only critical
endpoint—was low during a mean follow-up of 9.6 months. Dr
Zarins demonstrates that the results in this series are not differ-
ent than those from his previously reported prospective trial of
the AneuRx device nor of a large cumulative experience with
these devices.
However, it is becoming increasingly clear that, although
these devices can be inserted safely and with a high likelihood of
early technical success, these are in fact the least of the issue
regarding this form of treatment for aortic aneurysm. Data from
the Eurostar registry and Veith’s recent report to the American
Surgical Association (Ann Surg 2001;234:323-5) clearly suggest
that there is a steadily increasing risk of aneurysm expansion/
rupture or of major prosthesis complication requiring intervention,
probably at a 3% to 4% rate for each remaining year of the patient’s
life. Thus, it seems unreasonable to draw any conclusions from Dr
Zarins’ report, other than that of immediate technical success with
EVG insertion in community hospitals.
EVG was originally conceptualized for patients considered too
sick from various medical comorbidities to undergo an anesthetic
or an open operative repair of their aneurysm. In Dr Zarins’ series,
less than a third of patients (28%) underwent EVG placement for
this indication: almost three quarters could have undergone stand-
ard open aneurysm repair. On what basis was it deemed justified to
offer what is increasingly clearly a palliative EVG procedure to this
large number of aneurysm patients who could alternatively have
undergone a curative open repair?
Third, it is not even clear that those too sick to undergo a
standard open aneurysm repair, those for which seems most rea-
sonable, should be treated in this fashion. Eurostar data regarding
EVG treatment of such high-risk patients (Lancet 2000;356:832)
suggest that such intervention may accelerate their ultimate demise
in comparison with their life expectancy had they simply been left
alone. Would Dr Zarins comment on this observation?
It has become abundantly clear that safe and successful inser-
tion of an EVG, which Dr Zarins demonstrates can occur in the
community hospital setting, is not really the point. Rather, metic-
ulous, expert, and repetitive imaging studies of both the graft and
the treated aneurysm are obligatory in these patients. The persist-
ence or even late development of endoleaks, strut fractures, or
component dislocations must be aggressively sought and treated.
How confident can we be that the excellent technical expertise
demonstrated by these community hospital teams in inserting
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EVGs will be accompanied by equivalently fastidious follow-up of
treated patients?
Dr Christopher K. Zarins. Thank you, Dr Johansen, for
your comments. It is important to note that the results we are
reporting are the early results in community practice using an
FDA-approved endovascular device. The data from the Eurostar
registry and from Veith’s report to the American Surgical Society,
to which you refer, reflect endovascular experiences which include
a wide variety of endovascular devices, most of which are not
FDA-approved and many of which were early designs which have
subsequently been modified or withdrawn from use. Thus their
observations on the long-term outcome may not accurately reflect
outcomes using FDA-approved devices. We found that the early
results in community hospitals using an FDA-approved device
were no different from the results seen in the controlled clinical
trial using the same device. While we do not yet have long-term
data on these community patients, the published 4-year results
from the AneuRx clinical trial are quite favorable and there is no
reason to suspect that the long-term community results will be
different.
Dr Johansen’s comments reflect a common belief among
surgeons that endovascular repair is a short-term palliative proce-
dure whereas open surgical aneurysm repair provides a permanent
cure. The literature, however, is replete with reports of anasto-
motic aneurysms, graft thromboses, graft infections, aortoenteric
fistulas, and aneurysm ruptures following open repair. In our own
experience at Stanford, there was no difference in the need for a
secondary surgical procedure between patients undergoing open
or endovascular aneurysm repair. Open surgery patients, however,
had a higher mortality rate for both primary and secondary proce-
dures and had a significantly higher aneurysm-related death rate.
Precise comparisons between the two procedures will require
long-term prospective trials, however, at this point, we cannot
guarantee a patient a permanent cure with either open surgery or
endovascular repair and all aneurysm treatments are palliative and
require long-term follow up.
In this regard, the low (1%) operative mortality rate for
endovascular aneurysm repair in this community series is very
encouraging and is indeed the point of this paper. The mortality
rates in statewide or national databases for nonruptured open
surgical aneurysm repair are 7% to 8% with higher rates in hospitals
which perform few aneurysms repairs. While it is not possible to
know what the mortality rate would have been had the patients in
this series undergone open repair, it is highly unlikely that it would
have approached the 1% mortality observed, particularly since 29%
of the patients were too frail to undergo open surgery. Thus
endovascular aneurysm repair by properly trained and supported
teams may prove to be a safer procedure than open repair, partic-
ularly in hospitals where surgeons perform few open repairs.
In response to the question of whether endovascular repair
may have accelerated some high-risk patients’ demise, I would say
that this certainly would be true for the three patients who died
shortly after the procedure. The purpose of any aneurysm treat-
ment is to prevent death from rupture and a risk benefit assessment
considering the risk of rupture in light of the patient’s comorbidi-
ties and life expectancy must be made for each patient.
I agree with Dr Johansen’s comments on the need for fol-
low-up surveillance imaging and long-term follow-up of these
patients. While the early results of endovascular repair are very
promising, the long-term outcomes are not yet known. The good
news is that with physician training and proctoring, careful patient
selection, clinical support by the manufacturer, and ongoing edu-
cation of both the patient and physician, endovascular aneurysm
repair can be successfully introduced into community practice with
excellent early results.
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